(Reuters) – Gilead Sciences Inc
Findings from an analysis of its late-stage study showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company said.
Gilead shares were up nearly 2% at $76.14 before the bell.
(Reporting by Ankur Banerjee in Bengaluru; editing by Uttaresh.V)